开云app官网登录入口网页版-官方正版

#ALk阳性非小细胞肺癌#

19篇内容 | 968人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2185024, encodeId=247521850244f, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=李晓燕教授为ALK突变患者开启精准治疗新征程, objectType=article, longId=811472, objectId=27908114e264, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221107/1667834912742_8252897.webp, objectUrl=/article/show_article.do?id=27908114e264, replyNumber=0, likeNumber=65, createdTime=2024-01-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=27908114e264, moduleTitle=李晓燕教授为ALK突变患者开启精准治疗新征程, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=27908114e264)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1984836, encodeId=994d1984836ab, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究, objectType=article, longId=216851, objectId=7b11216851b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b11216851b9, replyNumber=0, likeNumber=69, createdTime=2022-07-04, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b11216851b9, moduleTitle=JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7b11216851b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984835, encodeId=8d361984835bc, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, objectType=article, longId=203570, objectId=632d2035e081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632d2035e081, replyNumber=0, likeNumber=67, createdTime=2021-05-02, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632d2035e081, moduleTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=632d2035e081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984834, encodeId=08c119848342c, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=56, createdTime=2020-10-18, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984833, encodeId=ce0119848336a, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, objectType=article, longId=184991, objectId=d09c18499171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d09c18499171, replyNumber=0, likeNumber=69, createdTime=2020-10-28, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d09c18499171, moduleTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d09c18499171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984831, encodeId=a5a2198483124, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=ALK阳性非小细胞肺癌病例分享, objectType=article, longId=151632, objectId=3d4415163229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4415163229, replyNumber=0, likeNumber=68, createdTime=2019-03-29, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4415163229, moduleTitle=ALK阳性非小细胞肺癌病例分享, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3d4415163229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984828, encodeId=7915198482869, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？, objectType=article, longId=149690, objectId=914b14969087, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914b14969087, replyNumber=0, likeNumber=0, createdTime=2018-11-21, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914b14969087, moduleTitle=【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=914b14969087)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984832, encodeId=50f6198483296, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌, objectType=article, longId=175747, objectId=f5121e574786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5121e574786, replyNumber=0, likeNumber=72, createdTime=2019-09-10, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5121e574786, moduleTitle=于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f5121e574786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984830, encodeId=679a198483000, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系, objectType=article, longId=150025, objectId=d10815002592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d10815002592, replyNumber=0, likeNumber=72, createdTime=2019-03-20, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d10815002592, moduleTitle=ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d10815002592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984827, encodeId=40da198482e99, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌, objectType=article, longId=141979, objectId=3d0a1419e91d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d0a1419e91d, replyNumber=0, likeNumber=68, createdTime=2018-09-09, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d0a1419e91d, moduleTitle=CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3d0a1419e91d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984829, encodeId=40461984829ed, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, objectType=article, longId=149829, objectId=2dc21498290c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc21498290c, replyNumber=0, likeNumber=76, createdTime=2018-12-09, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc21498290c, moduleTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2dc21498290c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984825, encodeId=62ce198482521, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者, objectType=article, longId=101275, objectId=d71d1012e5ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71d1012e5ac, replyNumber=0, likeNumber=123, createdTime=2017-11-03, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71d1012e5ac, moduleTitle=Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d71d1012e5ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984826, encodeId=5dd3198482678, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹, objectType=article, longId=111480, objectId=aacf11148072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aacf11148072, replyNumber=0, likeNumber=57, createdTime=2018-03-03, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aacf11148072, moduleTitle=NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aacf11148072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984821, encodeId=4ef4198482103, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼, objectType=article, longId=98487, objectId=f82a9848ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f82a9848ea1, replyNumber=0, likeNumber=74, createdTime=2017-12-01, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f82a9848ea1, moduleTitle=Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f82a9848ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984822, encodeId=8d2d1984822c3, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌, objectType=article, longId=100354, objectId=1e69100354f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e69100354f5, replyNumber=0, likeNumber=60, createdTime=2018-05-15, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e69100354f5, moduleTitle=诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e69100354f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984823, encodeId=2e2b198482363, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌, objectType=article, longId=100784, objectId=52ba100e84d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52ba100e84d9, replyNumber=0, likeNumber=78, createdTime=2018-01-19, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52ba100e84d9, moduleTitle=ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=52ba100e84d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984824, encodeId=ef611984824cc, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, objectType=article, longId=101153, objectId=1b50101153e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b50101153e0, replyNumber=0, likeNumber=88, createdTime=2017-10-20, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b50101153e0, moduleTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1b50101153e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984820, encodeId=cbdb198482051, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, objectType=article, longId=79864, objectId=5769e986481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5769e986481, replyNumber=0, likeNumber=62, createdTime=2017-03-19, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5769e986481, moduleTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5769e986481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984819, encodeId=6b29198481977, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物, objectType=article, longId=65871, objectId=541e658e142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541e658e142, replyNumber=0, likeNumber=94, createdTime=2016-05-10, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541e658e142, moduleTitle=JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=541e658e142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984818, encodeId=3a4919848187b, content=<a href='/topic/show?id=f7f5232e03' target=_blank style='color:#2F92EE;'>#ALk阳性非小细胞肺癌#</a>, objectTitle=NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌, objectType=article, longId=25138, objectId=454325138e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=454325138e0, replyNumber=0, likeNumber=137, createdTime=2014-05-09, rootId=0, userName=ms2186806800017884, userId=24c12500054, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454325138e0, moduleTitle=NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=454325138e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ALk阳性非小细胞肺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

李晓燕教授为ALK突变患者开启精准治疗新征程

2024-01-31发表于上海

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究

2022-07-04

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼

2021-05-02

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2020-10-18

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制

2020-10-28

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

ALK阳性非小细胞肺癌病例分享

2019-03-29

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？

2018-11-21

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌

2019-09-10

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系

2019-03-20

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌

2018-09-09

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率

2018-12-09

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者

2017-11-03

一叶知秋 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹

2018-03-03

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼

2017-12-01

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌

2018-05-15

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌

2018-01-19

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！

2017-10-20

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS

2017-03-19

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物

2016-05-10

ms2186806800017884 (审核中...)

前往app查看评论内容

#ALk阳性非小细胞肺癌#

NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌

2014-05-09

科室
- - 订阅+
  - 更多科室
工具
服务